Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluation of a Brief, Scalable Module to Mitigate Suicidal Ideation Among Youth (Phase 2)

23 de septiembre de 2026 actualizado por: Florida International University

This project embeds the "Give to Others" (GO) talk therapy module in a standard, outpatient therapy protocol to demonstrate target engagement in the context of ongoing clinical care and testing the ability of the GO module to engage the target in a rigorous randomized controlled trial (RCT) of the intervention. We will target perceived burdensomeness (PB) among 80 clinic-referred youths (ages 12-17) who experience subacute suicidal ideation (SI; i.e., positive suicide risk screen; stable safety status).

Descripción general del estudio

Descripción detallada

Youths will be recruited from the FIU Center for Children and Families (CCF) waitlist and the community at large, and will be randomized to one of the following 2 arms: a 12-session talk therapy and suicide risk management condition (control arm); and a 12-session therapy and suicide risk management condition plus the GO module (active arm). We hypothesize that youths receiving the GO module will have lower levels of PB and burden-related interpretation bias at mid-treatment and post-treatment compared with youths who receive the control arm. We also hypothesize that youths receiving the GO module will have lower levels of PB and burden-related interpretation bias at midtreatment and posttreatment compared to pre-treatment levels.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

80

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jeremy Pettit, PhD
  • Número de teléfono: 305-348-1671
  • Correo electrónico: jpettit@fiu.edu

Copia de seguridad de contactos de estudio

  • Nombre: Victor Buitron, PhD
  • Número de teléfono: 305-348-9880
  • Correo electrónico: vbuitron@fiu.edu

Ubicaciones de estudio

    • Florida
      • Miami, Florida, Estados Unidos, 33199
        • FIU Center for Children and Families
        • Investigador principal:
          • Victor Buitron, PhD
        • Contacto:
          • Jeremy Pettit, PhD
          • Número de teléfono: 305-348-1671
          • Correo electrónico: jpettit@fiu.edu
        • Contacto:
          • Victor Buitron, PhD
          • Número de teléfono: 305-348-9880
          • Correo electrónico: vbuitron@fiu.edu

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

Adolescents must:

  • be between ages 12 and 17 years
  • score at or above the clinical cutoff on the Revised Child Anxiety and Depression Scale
  • score at or above 4 on the Interpersonal Needs Questionnaire- Burdensomeness Scale
  • have a positive screen for suicide risk (i.e., endorsement of suicidal ideation via self-report)
  • be fluent in English and have available a parent who is fluent in English or Spanish

Exclusion Criteria

For adolescents to be excluded, they must:

  • have cognitive impairment or developmental delay which does not allow for the completion of basic study procedures (i.e., reading and filling out questionnaires; talking to a clinician)
  • show imminent risk or a history of hurting themselves or others requiring intensive and restrictive services
  • be involved currently in a psychosocial treatment

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: GO arm

Safety Planning + MATCH + GO module

Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.

The GO Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief follow-up.

The MATCH Anxiety and Depression modules involve a transdiagnostic protocol that adapts to individual clinical needs for teens experiencing internalizing symptoms. Participants receive weekly cognitive-behavioral therapy sessions guided by manualized decision flowcharts to sequence treatment strategies.

Comparador activo: Comparison Arm

Safety Planning + MATCH

Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.

The MATCH Anxiety and Depression modules involve a transdiagnostic protocol that adapts to individual clinical needs for teens experiencing internalizing symptoms. Participants receive weekly cognitive-behavioral therapy sessions guided by manualized decision flowcharts to sequence treatment strategies.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Interpersonal Needs Questionnaire- Burdensomenes Scale- Self-report at Mid-treatment
Periodo de tiempo: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)

5-item youth self-ratings on perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome).

From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
Suicide Risk and Ideation Scale for Kids (S-RISK) - Child Report at Mid-Treatment
Periodo de tiempo: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)

The S-RISK measures the severity and intensity of suicidal thoughts and capability via 20 items. Higher scores indicate higher severity of suicide risk.

From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
Interpersonal Needs Questionnaire- Burdensomenes Scale- Self-report at Post-treatment
Periodo de tiempo: From pre-treatment to post-treatment (within one week of completing the final CBT session)

5-item youth self-ratings on perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome).

From pre-treatment to post-treatment (within one week of completing the final CBT session)
Suicide Risk and Ideation Scale for Kids (S-RISK) - Child Report at Post-Treatment
Periodo de tiempo: From pre-treatment to post-treatment (within one week of completing the final CBT session)

The S-RISK measures the severity and intensity of suicidal thoughts and capability via 20 items. Higher scores indicate higher severity of suicide risk.

From pre-treatment to post-treatment (within one week of completing the final CBT session)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Interpersonal Needs Questionnaire- Burdensomenes Scale- Parent report at Mid-Treatment
Periodo de tiempo: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)

5-item parent ratings on youth perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome).

From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
Sentence Completion Task- Liability Index at Mid-Treatment
Periodo de tiempo: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)

28-item youth completed task assessing burden-related interpretation bias. Participants read 28 sentences indicative of posing a liability on others and select negatively- or positively-valenced words to complete each sentence. Each item is scored 0 or 1, yielding a total score between 0 and 28. Higher scores indicate higher levels of burden interpretation bias (worse outcome).

From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
Momentary Perceived Burdensomeness (mPB) Scale at Mid-Treatment
Periodo de tiempo: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)

The mPB scale was developed to capture real-time states of perceived burdensomeness (Lühr et al., 2026). mPB includes two self-report items rated 1 to 5 with higher scores indicating higher levels of burdensomeness.

From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
Interpersonal Needs Questionnaire- Burdensomenes Scale- Parent report at Post-Treatment
Periodo de tiempo: From pre-treatment to post-treatment (within one week of completing the final CBT session)

5-item parent ratings on youth perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome).

From pre-treatment to post-treatment (within one week of completing the final CBT session)
Sentence Completion Task- Liability Index at Post-Treatment
Periodo de tiempo: From pre-treatment to post-treatment (within one week of completing the final CBT session)

28-item youth completed task assessing burden-related interpretation bias. Participants read 28 sentences indicative of posing a liability on others and select negatively- or positively-valenced words to complete each sentence. Each item is scored 0 or 1, yielding a total score between 0 and 28. Higher scores indicate higher levels of burden interpretation bias (worse outcome).

From pre-treatment to post-treatment (within one week of completing the final CBT session)
Momentary Perceived Burdensomeness (mPB) Scale at Post-Treatment
Periodo de tiempo: From pre-treatment to post-treatment (within one week of completing the final CBT session)

The mPB scale was developed to capture real-time states of perceived burdensomeness (Lühr et al., 2026). mPB includes two self-report items rated 1 to 5 with higher scores indicating higher levels of burdensomeness.

From pre-treatment to post-treatment (within one week of completing the final CBT session)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Victor Buitron, PhD, Florida International University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

1 de julio de 2029

Finalización del estudio (Estimado)

1 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

23 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de septiembre de 2026

Publicado por primera vez (Actual)

29 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB-26-0416
  • R33MH137300 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

We will submit deidentified raw data to the National Institute of Mental Health (NIMH) Data Archive (NDA). The NDA is a data repository run by the NIMH that allows researchers studying mental health to collect and share deidentified information with each other. Our local data files will be coded, meaning we can track data back to subjects via a master key. However, we will upload de-identified electronic raw data collected from questionnaires and interviews to the NDA.

Marco de tiempo para compartir IPD

The scientific community will have access to data when the award ends. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir